F35F85A8-B3CD-4116-990F-94B2E432F902
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6.701708278580814
- age_years
- 20
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.493
- NOTCH_SIGNALING+0.472
- PROTEIN_SECRETION+0.422
- MYC_TARGETS_V1+0.407
- WNT_BETA_CATENIN_SIGNALING+0.397
- MITOTIC_SPINDLE+0.393
- UNFOLDED_PROTEIN_RESPONSE+0.331
- G2M_CHECKPOINT+0.329
- ADIPOGENESIS+0.316
- MYC_TARGETS_V2+0.298
Top 10 suppressed
- KRAS_SIGNALING_DN-0.388
- ANGIOGENESIS-0.241
- SPERMATOGENESIS-0.238
- PANCREAS_BETA_CELLS-0.199
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.177
- COAGULATION-0.167
- MYOGENESIS-0.165
- INTERFERON_ALPHA_RESPONSE-0.086
- INTERFERON_GAMMA_RESPONSE-0.069
- APICAL_JUNCTION-0.063
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F19C96EE-D936-4385-B543-07FA8447A3DD | — | — | 0.905 |
| 2 | SRR934870 | — | — | 0.899 |
| 3 | 53BA607F-7939-40D9-BEFA-DC4ABDC7630B | — | — | 0.896 |
| 4 | BE6A3670-34C4-4FD3-9794-C5B3254D9224 | — | — | 0.894 |
| 5 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.892 |
| 6 | 6B66F14C-7616-4DEC-A604-2168DBA50A1B | — | — | 0.890 |
| 7 | AE32CA37-A422-42E3-AA29-0149CF1A3019 | — | — | 0.878 |
| 8 | 4099642A-F8D6-428C-AA12-1E76C27BB368 | — | — | 0.878 |
| 9 | 67B5E93E-6F06-4247-86DD-A914279EFFC5 | — | — | 0.877 |
| 10 | 7779D220-647F-4D6C-890B-022208B51F57 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.493 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.472 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.422 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.407 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.397 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.393 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.331 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.329 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.316 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.298 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.250 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.247 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.246 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.244 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.226 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.226 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.219 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.211 | Inavolisib | — uncovered |
| PEROXISOME | 0.203 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.202 | Inavolisib | — uncovered |